You cannot register anymore for this webinar

ECM Pharmacology Symposium

Extracellular matrix (ECM) dysregulation is the founding cause of tissue fibrosis, a process driving more than 50 pathologies and most chronic diseases. Fibrosis may develop both consequent to either an increase in tissue formation or a decrease in tissue degradation.

​​​​​​​Understanding the ECM and the central components of the basement membrane and interstitial ECM will lead to a better understanding of disease mechanisms and to novel treatment strategies. This may be a central part in precision medicine strategies to target the right patients.

​​​​​​​Learn more here: Webinars - ECM Congress (ecm-congress.org)
Want to watch the replay? Click here!

Presentation by
Dr. Morten Karsdal
  • ECM remodeling is the common denominator of all fibro-inflammatory disorders
  • Collagens have signaling molecules that we need to understand to understand how the ECM affects cells in fibrosis and tissue turnover
  • Endotrophin and other collagen fragments (Vastatin, Tumstatin and Endostatin) are potential signaling molecules derived from the processing of the collagens in the ECM
  • Understanding ECM turnover may lead to better insight into disease mechanisms and better biological understanding of individual patients

Dr. Alexander Lynge Reese-Petersen
  • ECM biomarkers are elevated in chronic pathologies and have prognostic significance for outcome. How can we best use this to guide drug development?
  • Endotrophin, a collagen hormone in multi-organ diseases
  • Endotrophin in HFpEF, a potentially treatable high-risk endotype
  • Use of the tissue turnover profile for patient selection

Duration
90 minutes

Share this webinar